Should an oral glucose tolerance test be performed routinely in all renal transplant recipients?

Kirsten A. Armstrong; Johannes B. Prins; Elaine M. Beller; Scott B. Campbell; Carmel M. Hawley; David W. Johnson; Nicole M. Isbel

doi:10.2215/CJN.00090605

Should an oral glucose tolerance test be performed routinely in all renal transplant recipients?

Kirsten A. Armstrong^*, Johannes B. Prins, Elaine M. Beller, Scott B. Campbell, Carmel M. Hawley, David W. Johnson, Nicole M. Isbel

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

53 Citations (Scopus)

Abstract

Posttransplantation diabetes (PTD) contributes to cardiovascular disease and graft loss in renal transplant recipients (RTR). Current recommendations advise fasting blood glucose (FBG) as the screening and diagnostic test of choice for PTD. This study sought to determine (1) the predictive power of FBG with respect to 2-h blood glucose (2HBG) and (2) the prevalence of PTD using FBG and 2HBG compared with that using FBG alone, in prevalent RTR. A total of 200 RTR (mean age 52 yr; 59% male; median transplant duration 6.6 yr) who were >6 mo posttransplantation and had no known history of diabetes were studied. Patients with FBG

Original language	English
Pages (from-to)	100-108
Number of pages	9
Journal	Journal of the American Society of Nephrology : JASN
Volume	1
Issue number	1
DOIs	https://doi.org/10.2215/CJN.00090605
Publication status	Published - Jan 2006
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.2215/CJN.00090605

Cite this

@article{8a1482d756b249aeb1b6384468d15c38,

title = "Should an oral glucose tolerance test be performed routinely in all renal transplant recipients?",

abstract = "Posttransplantation diabetes (PTD) contributes to cardiovascular disease and graft loss in renal transplant recipients (RTR). Current recommendations advise fasting blood glucose (FBG) as the screening and diagnostic test of choice for PTD. This study sought to determine (1) the predictive power of FBG with respect to 2-h blood glucose (2HBG) and (2) the prevalence of PTD using FBG and 2HBG compared with that using FBG alone, in prevalent RTR. A total of 200 RTR (mean age 52 yr; 59% male; median transplant duration 6.6 yr) who were >6 mo posttransplantation and had no known history of diabetes were studied. Patients with FBG",

author = "Armstrong, {Kirsten A.} and Prins, {Johannes B.} and Beller, {Elaine M.} and Campbell, {Scott B.} and Hawley, {Carmel M.} and Johnson, {David W.} and Isbel, {Nicole M.}",

year = "2006",

month = jan,

doi = "10.2215/CJN.00090605",

language = "English",

volume = "1",

pages = "100--108",

journal = "Journal of the American Society of Nephrology : JASN",

issn = "1046-6673",